Brief: Rosetta Genomics to acquire PersonalizeDX

Rosetta Genomics

09/04/2015 17:16

April 9 (Reuters) - Rosetta Genomics Ltd  ROSG.O : 
 * To acquire PersonalizeDX 
 * Says purchase price includes $2.0 million in cash, 500,000 ordinary shares of 
   Rosetta Genomics Ltd 
 * Says expects annualized pro forma 2015 revenues of $10 million to $12 
   million, and 2016 revenues to exceed $18 million 
 * Says Rosetta Genomics will gain rights to market prelude's novel assay for 
   ductal carcinoma in situ (DCIS) 
 * Says expects to achieve positive EBITDA and positive cash flow from 
   operations prior to the end of 2017 
 
* Source text for Eikon  ID:nBw5Nzkmka  
 
* Further company coverage  ROSG.O  
 ((Bengaluru Newsroom; +1 646 223 8780))